We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -1.20% | 2.05 | 1,136,277 | 12:36:34 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.00 | 2.10 | 2.075 | 2.025 | 2.075 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.09M | -33.29M | -0.0429 | -0.48 | 16.09M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:04:34 | O | 100,000 | 2.0675 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/7/2024 | 15:27 | ALNC |  EXECUTIVE CHANGES: Morgan Advanced Materials picks senior director |
| 24/7/2024 | 07:01 | UK RNS | Shield Therapeutics PLC Unaudited Q2 2024 Trading Update |
| 24/7/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Directorate Change |
| 03/7/2024 | 16:26 | ALNC | EARNINGS AND TRADING: ActiveOps makes profit; Contango gets investment |
| 03/7/2024 | 07:00 | UK RNS | Shield Therapeutics PLC $5.7m Milestone Monetization Agreement with AOP |
| 20/6/2024 | 16:25 | UK RNS | Shield Therapeutics PLC Results of 2024 Annual General Meeting |
| 28/5/2024 | 20:32 | ALNC | TRADING UPDATES: NetScientific backs Wanda; Inspirit Energy wins deal |
| 28/5/2024 | 07:00 | UK RNS | Shield Therapeutics PLC New Drug Application for Accrufer® in South Korea |
| 10/5/2024 | 15:30 | UK RNS | Shield Therapeutics PLC Audited results for the year ended 31 Dec 2023 |
| 30/4/2024 | 19:54 | ALNC | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue |
Shield Therapeutics (STX) Share Charts1 Year Shield Therapeutics Chart |
|
1 Month Shield Therapeutics Chart |
Intraday Shield Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 11:51 | STX Shield Therapeutics Plc | 36 |
| 26/7/2024 | 07:07 | Shield Therapeutics: poised for a US licensing deal | 14,100 |
| 25/7/2024 | 10:42 | Shield Therapeutics moderated | 9 |
| 02/5/2024 | 08:14 | Shield Therapeutics | 4,114 |
| 22/2/2024 | 08:59 | Shield therapeutics what next? | 1,974 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:04:35 | 2.07 | 100,000 | 2,067.50 | O |
| 2024-07-26 14:54:01 | 2.07 | 4,263 | 88.14 | O |
| 2024-07-26 14:26:30 | 2.01 | 50,000 | 1,005.00 | O |
| 2024-07-26 14:21:22 | 2.07 | 244 | 5.04 | O |
| 2024-07-26 14:20:40 | 2.07 | 873 | 18.05 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Shield Therapeutics Daily Update Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.08p.Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £15,896,302. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.48. This morning STX shares opened at 2.08p |
Posted at 24/7/2024 18:48 by r9505571 Shield Therapeutics (LON:STX) is currently experiencing a challenging period. Its stock price has been highly volatile, recently trading at around 1.60 GBX, representing a significant decline over the past year [oai_citation:1,Shie |
Posted at 11/7/2024 11:16 by socionomics Focus on the facts as we know them.1) Commercial stage drug selling in the £millions. 2) Cash runway to 2025 (now even further out given the latest cash windfall) 3) An offer of 6.2p per share was received last year from the largest shareholder. 4) The largest shareholder has put their top guy on the STX board recently. 5) Prescriptions increasing exponentially. All of the above is accurate to the best of my knowledge. Don't let the share price put you off. It's primed for takeoff. |
Posted at 05/7/2024 09:49 by r9505571 Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved.2024 revenue forecast increased from US$30.8m to US$33.3m.EPS estimate increased from -US$0.03 per share to -US$0.026 per share.Pharmaceutical |
Posted at 03/7/2024 14:08 by base7 I appreciate that , while this deal is expensive for STX, it provides an extension to our cash runway thereby proving an improved chance that we can demonstrate a move towards break even then profitability + we have a hugely successful entrepreneur on our Board .That said - if it is a great deal for STX & suggests that our share price should realistically be 5/6p, I would expect Greg & CFO to be buying as many as they can in the market & they can hardly claim a financial inability to buy a few million shares under 2p with view to their packages. |
Posted at 22/5/2024 14:49 by qipincha the share price was around 12p sep last year. This is significantly undervalued.As the share price is recovering, It is expected it will soon go back to 3p 6p and 12p. Whether it can go beyond and when is depending on how quickly the company can sell enough volume to make a profit |
Posted at 17/5/2024 19:50 by r9505571 Shield TherapeuticsSTXShare Price 7 Day 1 Year0.02 21.3% -73.2% Consensus revenue estimates fall by 34%The consensus outlook for revenues in fiscal year 2024 has deteriorated.2024 revenue forecast decreased from US$45.6m to US$30.3m.Forecast losses increased from -US$0.026 to -US$0.027 per share.Pharmaceutical |
Posted at 25/4/2024 11:09 by ih_676530 The share price is heavily oversold on the tech chart,especially after today's drop. This should draw in value and chart traders. If Tuesday's results are as good as February's trading update then the share price could easily double in value in a single day. |
Posted at 04/4/2024 18:19 by bolitix Now i lost lots to these clowns so have now written that loss off. I did say this CEO would drag this share price near a penny some time ago. Now the worst could well be on the cards if they do a share exchange for the new company on a 1:10, 1:100 or even 1:1000 ratio to hype the price up on a Par so if 1:1000 the share price per share will be increased by a factor of 1000 to compensate but that will immediately drop lower. Hence, stay away from this company until it changes this CEO and its mindset. |
Posted at 27/2/2024 15:05 by bolitix I said a couple of months ago this CEO will take this below 1p share price Even with a 200% sales gain over 2023 he has managed to take the share price down 25 fold to date. VTRS share price is about 13p and i dont know AOPs but which of these who take over we cant expect the share price to ever top theirs. Now i am not gloating here as i have lost lots on STX! |
Posted at 23/2/2024 15:38 by base7 Greg talks a great story but has delivered an almost 100% write down in our share price since he took control.Our share price was recovering nicely at 12/13p until the disastrous 8p raise accompanied by disgraceful & obvious insider trading.AS ever, The Regulator did nothing & those shorting got away with it again.This weeks debacle of over stated prescription targets was another disgrace & either Greg of the CFO should have had an eye or two on that ball-resulting in cashflow break even being pushed back another 6-12 months & Greg & Santosh saying with confidence that we have sufficient cash to achieve that target must be taken with a pinch of salt or our share price would have recovered to the heady heights of 5p.Greg has been in situ for long enough to sort out Norgine but they continue plodding along doing very little with their rights to sell our products in a market of 500m potential patients - surely we should potentially generate more revenue from Europe than US. The only near term prospective good news is from Korea & Canada where we should soon be generating revenue - although that too is already several months behind schedule. The only other action Greg & Santosh could now take to give The Market a sign of their confidence is to invest a relatively small amount of their large packages on a substantial number of share + take some of their remuneration in shares.If I was running a company which I had total belief in I would want as many shares as possible-especially with our share price at a 60%+ discount to the 8p raise . Rant over - fine weekend to you all ! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
